Hormonal
Genetically proxied GLP-1R-based multi-target agonists (GIPR/GLP-1R, GCGR/GLP-1R, and GCGR/GIPR/GLP-1R) causally reduce the risk of Metabolic dysfunction-associated steatotic liver disease (MASLD) and its complications, including liver cancer and cardiovascular disease, partly independent of weight loss.
Genetic evidence strongly supports that GLP-1-based therapies (like semaglutide or tirzepatide) reduce the risk of fatty liver disease and its complications (liver cancer, heart disease). This benefit appears to come from improving metabolic health (insulin sensitivity, lipids) directly, not just from losing weight. If you have MASLD, these medications are a promising therapeutic option to discuss with your doctor, regardless of your current weight loss progress.
The MR analyses suggested genetically proxied GLP-1R-based agonists were causally associated with a reduced risk of MASLD... Furthermore, these agonists also exhibited protective effects against liver cancer and cardiovascular diseases... We identified the causal role of GLP-1R-based agonists in reducing the risk of MASLD and its complications, probably by improving systemic metabolic disorders and partly independent of their weight-loss effect.
Why this rating
High-quality observational evidence via Mendelian Randomization with multiple sensitivity analyses and replication cohorts, though not a direct clinical trial of the drug itself.
Source
Systemic evaluation of the effects of monomeric GLP-1R-based agonists on MASLD and its complications
Yangke Cai et al. · Diabetology & Metabolic Syndrome · 2025
DOI 10.1186/s13098-025-01870-x
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →